HomeALCLS • EPA
add
Cellectis SA
Previous close
€1.74
Day range
€1.69 - €1.72
Year range
€1.41 - €3.03
Market cap
122.62M EUR
Avg Volume
66.82K
P/E ratio
-
Dividend yield
-
Primary exchange
EPA
Market news
Financials
Income Statement
Revenue
Net income
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Revenue | 18.05M | 997.99% |
Operating expense | 28.82M | 29.16% |
Net income | -23.06M | -31.88% |
Net profit margin | -127.73 | 87.99% |
Earnings per share | -0.22 | 40.54% |
EBITDA | -8.00M | 55.99% |
Effective tax rate | 0.26% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 159.09M | 136.18% |
Total assets | 395.88M | 88.78% |
Total liabilities | 266.45M | 99.47% |
Total equity | 129.42M | — |
Shares outstanding | 100.09M | — |
Price to book | 1.35 | — |
Return on assets | -6.71% | — |
Return on capital | -11.77% | — |
Cash Flow
Net change in cash
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Net income | -23.06M | -31.88% |
Cash from operations | -5.83M | 65.90% |
Cash from investing | 22.33M | 7,544.33% |
Cash from financing | -4.22M | -349.88% |
Net change in cash | 10.05M | 159.00% |
Free cash flow | 23.63M | 366.56% |
About
Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina. Wikipedia
Founded
1999
Website
Employees
219
